CDMO Adragos Pharma Completes Expansion With New Ampoule Fill/Finish Line In France

Adragos Pharma, a leading Contract Development and Manufacturing Organization (CDMO), has significantly bolstered its production capabilities with the completion of a state-of-the-art ampoule filling line at its Livron-sur-Drôme facility in France.

With a €13 million investment, the new line increases the site’s production capacity by 30%, enabling Adragos Pharma to produce over 160 million ampoules annually. This expansion is designed to meet the rising global demand for sterile injectables, reinforcing the company's position in the pharmaceutical market.

The new line, the fourth at the facility, offers flexible fill volumes ranging from 1ml to 20ml, making it ideal for a broad range of formulations and customer-specific requirements. It also supports aseptic filling and finishing in full compliance with Annex 1 of EU GMP regulations, ensuring Adragos Pharma maintains the highest standards of quality and regulatory compliance while providing tailored solutions to clients.

Beyond increasing capacity, this expansion enhances the company’s operational efficiency, allowing Adragos Pharma to respond more swiftly to market demands and strengthen its reputation as a trusted partner in the pharmaceutical sector.

In addition to the new filling line, the Livron facility has been upgraded with a cutting-edge cleanroom, further optimizing the site’s manufacturing capabilities. Gaël Le Saux, Site Head of Livron, praised the team’s successful execution of the project: "Despite the complexities, our team managed to integrate the new production line seamlessly without disrupting ongoing operations."

About Adragos Pharma:   

Adragos Pharma is a globally operating CDMO with headquarters in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America, and Japan to attain a globally leading position within the next few years and set new standards in customer service and data centricity. In its buy-and-build growth strategy, Adragos Pharma is supported by FSN Capital, a leading Scandinavian investment firm. Adragos Pharma currently operates four production sites in France, Germany, Norway, and Japan and a development site in Greece.